Abstracts tagged "lymphocytes"

Abstract Number: 1825 • 2016 ACR/ARHP Annual Meeting
the Non-Coding Genome and the Genetics of Systemic Lupus
Joyce Hui-Yuen¹, Lisha Zhu², Lai Ping Wong³, Kaiyu Jiang⁴, Yanmin Chen⁴, Tao Liu⁵ and James Jarvis⁶, ¹North Shore-Long Island Jewish Health System, Lake Success, NY, ²Biochemistry, University at Buffalo, Buffalo, NY, ³Pediatrics, University at Buffalo, Buffalo, NY, ⁴Pediatrics, The University at Buffalo, Buffalo, NY, ⁵Department of Biochemistry, University at Buffalo, Buffalo, NY, ⁶Pediatrics, SUNY Buffalo School of Medicine, Buffalo, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is a multi-system, complex disease believed to be triggered by gene-environment interactions. While we have made considerable progress in investigation…
Abstract Number: 2569 • 2016 ACR/ARHP Annual Meeting
Restoration of Decreased Lymphocyte Counts and the Shift to Th1 and Effector Memory CD8+T Cell Subsets Associate with Spontaneous Regression of Lympho-Proliferative Disorders Developed in RA Patients Treated with Methotrexate
Shuntaro Saito¹, Katsuya Suzuki¹, Kunihiro Yamaoka¹, Koichi Amano², Michihide Tokuhira³ and Tsutomu Takeuchi¹, ¹Keio University School of Medcine, Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan, ²Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan, ³Department of Hematology, Saitama Medical Center, Saitama Medical University., Saitama, Japan
Background/Purpose: Methods: Forty-three RA patients complicated with LPD were identified and 76 control patients were selected. Among the 43 LPD patients, 28 were regressive and…
Abstract Number: 738 • 2015 ACR/ARHP Annual Meeting
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the BCL-2 Inhibitor Venetoclax (ABT-199) in a Phase 1 Single and Multiple Ascending Dose Study in Female Patients with Systemic Lupus Erythematosus
Peng Lu¹, Roy Fleischmann², Craig Curtis³, Stanislav Ignatenko⁴, Monali Desai⁵, Shekman L. Wong⁵, Kristie M. Grebe¹, Jiewei Zeng⁵, Jeroen Medema⁵ and James Stolzenbach⁵, ¹AbbVie Inc., Worcester, MA, ²University of Texas Southwestern Medical Center, Dallas, TX, ³Compass Research Center, Orlando, FL, ⁴Charité Research Organization, Berlin, Germany, ⁵AbbVie Inc., North Chicago, IL
Background/Purpose: Apoptosis is needed to eliminate auto-reactive T and B cells during immune responses; failure of elimination is important in development of systemic lupus erythematosus…
Abstract Number: 1985 • 2015 ACR/ARHP Annual Meeting
Abnormal B-Cell Distribution Is Improved By Tocilizumab Monotherapy in Patients with Polymyalgia Rheumatica
Guillermo Carvajal Alegria¹, Valerie Devauchelle², Yves Renaudineau³, Alain Saraux⁴, Jacques-Olivier Pers⁵ and Divi Cornec⁶, ¹Immunology, CHRU MORVAN, BREST, France, ²Service de Rhumatologie, CHU Brest, Brest, France, ³Immunology, Brest University Medical School Hospital, Brest, France, ⁴Rheumatology Department, CHU de la Cavale Blanche, Brest Cedex, France, ⁵EA2216/ERI29 UBO, Brest, France, ⁶Department of rheumatology, Brest Occidentale University, Brest, France
Background/Purpose: Abnormalities in B-cell population distribution were recently reported in polymyalgia rheumatica (PMR) and giant cell arteritis, which improved with glucocorticoids. Our objective here was…
Abstract Number: 538 • 2015 ACR/ARHP Annual Meeting
Multidrug Resistant Lymphocytes of Patients with Rheumatoid Arthritis Are Predictive for DMARD and Glucocorticoid Treatment Response
Jan Piet van Hamburg¹, Sandra M.J. Paulissen², Nadine Davelaar¹, Mieke Hazes³ and Erik Lubberts¹, ¹Rheumatology and Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands, ²Room Nb-84, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands, ³Rheumatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands
Background/Purpose: A large fraction of patients with RA does not respond to treatment with glucocorticoids (GCs) and disease-modifying anti-rheumatic drugs (DMARDs), or becomes resistant in…
Abstract Number: 569 • 2015 ACR/ARHP Annual Meeting
Neurophil to Lymphocyte Ratio Is a Reliable Marker of Treatment Response in Rheumatoid Arthritis Patients during Tocilizumab Therapy
Byeongzu Ghang¹, Doo-Ho Lim², Soo Min Ahn³, Wook Jang Seo⁴, Seokchan Hong³, Yong-Gil Kim², Chang-Keun Lee² and Bin Yoo², ¹Division of Rheumatology, Department of Internal Medicine, Univerisy of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Department of Rheumatology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, ³Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, ⁴Internal Medicine, Seoul Veterans Hospital, Seoul, South Korea
Background/Purpose: Tocilizumab, an interleukin-6 (IL-6) receptor antagonist, is an effective drug for the treatment of rheumatoid arthritis (RA). During administration of tocilizumab, previous studies have…
Abstract Number: 508 • 2014 ACR/ARHP Annual Meeting
Relationship Between NK Cell Count and Important Safety Events in Rheumatoid Arthritis Patients Treated with Tofacitinib
R. van Vollenhoven¹, Y. Tanaka², R. Riese³, M. Lamba³, T. Kawabata³, T. Hirose⁴, S. Toyoizumi⁴, A. Hazra³ and S. Krishnaswami³, ¹The Karolinska Institute, Stockholm, Sweden, ²University of Occupational and Environmental Health, Kitakyushu, Japan, ³Pfizer Inc, Groton, CT, ⁴Pfizer Inc, Tokyo, Japan
Background/Purpose: Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Cytokines (e.g. interleukin [IL]-2, -4, -7, -15, -21) involved…
Abstract Number: 2330 • 2013 ACR/ARHP Annual Meeting
Relationship Between Lymphocyte Count and Risk Of Infection In Rheumatoid Arthritis Patients Treated With Tofacitinib
R. F. van Vollenhoven¹, R. Riese², S. Krishnaswami², T. Kawabata², C. Fosser², S. Rottinghaus², M. Lamba² and S. H. Zwillich², ¹Clinical Trials Unit Department of Rheumatology, The Karolinska Institute, Stockholm, Sweden, ²Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is a novel oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Cytokines involved in lymphocyte development, function and homeostasis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].